Tango Therapeutics, Inc. TNGX

24.92 0.29 1.18% as of 25 Sep
Market cap
$4.2B
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 — —
P/S ratio
16.50 8.02 25.84 25.82 18.34 0.00 — —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 — —
P/Operating CF
(34.63) (9.21) (34.36) (22.71) (40.20) (1,027.12) — —
P/B ratio
2.97 1.69 3.73 2.57 1.97 1.51 — —
Price to Tangible BV
2.97 1.69 3.73 2.57 1.97 1.51 — —
EV/Sales
10.99 1.89 16.59 11.07 5.23 0.00 — —
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 — —
EV/Operating CF
(4.94) (0.61) (5.14) (2.52) (3.25) 0.00 — —
EV/FCF
(4.90) (0.60) (5.07) (2.36) (3.16) 0.00 — —
Quick Ratio
15.85 6.76 7.35 6.64 11.99 4.70 — —
Current Ratio
16.32 6.98 7.54 6.76 12.10 4.73 — —
Net Debt/EBITDA
3.08 1.75 2.93 3.35 8.48 3.70 — —
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 — —
Asset Turnover
0.17 0.12 0.09 0.05 0.10 0.07 0.00 —
Operating CF/Net income
1.37 1.01 1.16 1.01 1.02 (1.35) — —
Capex/Depreciation
2.57 0.36 1.56 (4.78) (2.05) (1.54) — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 — —
ROE
(37.23%) (57.58%) (40.49%) (36.41%) (30.38%) (20.50%) — —
ROA
(28.41%) (36.24%) (24.25%) (23.10%) (16.46%) (50.15%) 0.00% —
ROIC
(2,661.91%) 0.00% 0.00% 0.00% 0.00% 0.00% — —
Return on Tangible Assets
(29.97%) (55.15%) (32.77%) (32.72%) (12.76%) (33.20%) — —
Average Days of Receivables
0.00 0.00 0.00 29.36 19.71 95.35 — —
Research and Development Expense of Revenue
211.86% 342.10% 315.38% 426.01% 209.59% 652.96% — —
Selling, General and Administrative Expense of Revenue
66.54% 103.99% 97.19% 120.78% 47.50% 128.85% — —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
42.37% 68.69% 52.23% 57.24% 21.15% 23.04% — —
Graham Net Nets
0.29 0.44 0.21 0.29 0.50 (0.02) — —
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 — —
Earnings Yield
(9.71%) (39.16%) (11.02%) (16.83%) (8.58%) 0.00% — —
Free Cash Flow Yield
(13.60%) (39.19%) (12.66%) (18.19%) (9.03%) 0.00% — —
Revenue per Share
0.54 0.39 0.39 0.28 0.60 0.24 — —
Operating CF per Share
(1.20) (1.20) (1.25) (1.24) (0.96) 2.19 — —
Capex per Share
(0.01) (0.01) (0.02) (0.09) (0.03) (0.03) — —
Free Cash Flow per Share
(1.20) (1.21) (1.26) (1.33) (0.99) 2.16 — —
Cash per Share
2.96 2.36 3.57 4.18 7.82 5.96 — —
Shareholders Equity per Share
2.98 1.83 2.68 2.84 5.55 1.21 — —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 — —
Book value per Share
2.98 1.83 2.68 2.84 5.55 1.21 — —
Free Cash Flow
(139.93) (132.25) (119.51) (116.77) (61.36) 68.97 — —
Working Capital
332.08 228.17 300.60 319.73 451.65 152.72 — —
Capital Expenditures
(1.05) (0.75) (1.53) (7.69) (1.84) (1.11) — —
Net Current Asset Value
301.25 149.37 197.08 188.28 336.93 24.98 — —
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 — —
Capex to Sales
0.02 0.02 0.04 0.31 0.05 0.14 — —
Net Profit Margin
(162.85%) (309.73%) (278.54%) (435.14%) (157.21%) (678.84%) — —
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 — —
Other line items
Depreciation/Fixed assets
(0.06) (0.26) (0.10) 0.15 0.19 0.19 — —
Cash ROIC
(21.13%) (30.52%) (21.65%) (19.47%) (7.75%) 28.94% — —
Accounts Receivable Turnover
0.00 0.00 0.00 12.43 18.52 3.83 — —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 — —
Inventory Turnover
— — — 0.00 0.00 0.00 — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 — —
Days of Inventory on Hand
— — — 0.00 0.00 0.00 — —
Average Receivables
— — — 2.00 2.00 2.00 — —
Average Payables
1.39 2.19 3.62 3.84 2.53 2.53 — —
Average Assets
357.59 359.53 419.52 468.31 353.70 103.63 0.00 —
Average Common Equity
272.85 226.31 251.29 297.11 191.67 253.55 — —

Fold the line items

Columns are period end dates